Fig. 6: MRTX1257 treatment is correlated with increased vimentin expression and tumour vascularisation.

a Plot depicting the contribution of the mean intensity of markers per mouse that have contributed to the first two principal components (PC1 and PC2 on and x and y axis, respectively) of the PCA analysis from Supplementary Fig. 4c. b Mean intensity of vimentin per ROI, separated by treatment group on the x-axis. Points are coloured by mouse ID as indicated in the legend. P value = 0.03, extracted from ANOVA testing of linear mixed-effects model. c Distribution of vimentin expression across cell types separated by treatment, means are indicated with a dot. ANOVA testing of a linear mixed-effects model found that the two treatment conditions had a significantly different vimentin expression profile across the cell types (P < 0.0001 for treatment:cell type), and that these differences were significant for Endothelium (P-adj = 0.04) and Epithelium (P-adj = 0.02, corrected for multiple testing by adjusting for false discovery rate (FDR)). d Crop of PECAM and vimentin expression in a tumour treated with MRTX1257. For visualisation purposes, the images were processed in Fiji with a median filter (radius 0.5). e Vimentin expression and proportion of endothelium cells in the tissue are positively correlated for the MRTX1257 treated ROIs, but not for the vehicle-treated ROIs (two-sided Pearson correlation testing, not adjusted for multiple testing). No other correlations between cell type and vimentin expression were found to be significant. f Pearson correlation matrix of cell type proportions in the tumour domain of MRTX1257 treated tumours, extracted from the linear mixed-effects model using the mouse:ROI estimates. MRTX MRTX1257.